New spesolimab data show significant improvement in GPP flares
New spesolimab data show significant improvement in GPP flares
Search
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Transforming Science Day Europe
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Breakthrough introduction innovation pet parasiticides
In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Pet parasites are still here. What's the risk?
What's the risk of pet parasites? They’re a growing challenge due to climate change. Check how to protect your dog and cat from fleas, ticks and more.
Diabetes
Diabetes
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
The power of patient advocacy in cancer care
Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Our Health and Safety initiative - BE SAFE
Health and safety are of great importance to Boehringer Ingelheim.
Generalised-Pustular-Psoriasis-Infographic
What is GPP? GPP is a rare and chronic autoinflammatory skin disease with recurrent episodes of exacerbations or flares
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
EURICAN® L4
Canine vaccine against leptospirosis
Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Exploring beyond boundaries for innovation in animal health
Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.
More Than Scleroderma
A hub of knowledge, advice and support for those whose lives have been touched by scleroderma.
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
Brand of the Year Frontline pet parasiticides
FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Empowering smallholder farmers
The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
Hidradenitis suppurativa
Find out more about hidradenitis suppurativa (HS), a long-term, inflammatory, recurrent, skin disease
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements